These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 34943700)

  • 1. Lefamulin in Patients with Community-Acquired Bacterial Pneumonia Caused by Atypical Respiratory Pathogens: Pooled Results from Two Phase 3 Trials.
    Paukner S; Mariano D; Das AF; Moran GJ; Sandrock C; Waites KB; File TM
    Antibiotics (Basel); 2021 Dec; 10(12):. PubMed ID: 34943700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pooled microbiological findings and efficacy outcomes by pathogen in adults with community-acquired bacterial pneumonia from the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 phase 3 trials of lefamulin versus moxifloxacin.
    Paukner S; Goldberg L; Alexander E; Das AF; Heinrich S; Patel P; Moran GJ; Sandrock C; File TM; Vidal JE; Waites KB; Gelone SP; Schranz J
    J Glob Antimicrob Resist; 2022 Jun; 29():434-443. PubMed ID: 34788694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lefamulin efficacy and safety in a pooled phase 3 clinical trial population with community-acquired bacterial pneumonia and common clinical comorbidities.
    File TM; Alexander E; Goldberg L; Das AF; Sandrock C; Paukner S; Moran GJ
    BMC Pulm Med; 2021 May; 21(1):154. PubMed ID: 33964925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral 5-Day Lefamulin for Outpatient Management of Community-Acquired Bacterial Pneumonia: Post-hoc Analysis of the Lefamulin Evaluation Against Pneumonia (LEAP) 2 Trial.
    LoVecchio F; Schranz J; Alexander E; Mariano D; Meads A; Sandrock C; Moran GJ; Giordano PA
    J Emerg Med; 2021 Jun; 60(6):781-792. PubMed ID: 33731270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial.
    File TM; Goldberg L; Das A; Sweeney C; Saviski J; Gelone SP; Seltzer E; Paukner S; Wicha WW; Talbot GH; Gasink LB
    Clin Infect Dis; 2019 Nov; 69(11):1856-1867. PubMed ID: 30722059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Community-Acquired Pneumonia: A Focus on Lefamulin.
    Eraikhuemen N; Julien D; Kelly A; Lindsay T; Lazaridis D
    Infect Dis Ther; 2021 Mar; 10(1):149-163. PubMed ID: 33528794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial.
    Alexander E; Goldberg L; Das AF; Moran GJ; Sandrock C; Gasink LB; Spera P; Sweeney C; Paukner S; Wicha WW; Gelone SP; Schranz J
    JAMA; 2019 Nov; 322(17):1661-1671. PubMed ID: 31560372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia.
    Zhanel GG; Deng C; Zelenitsky S; Lawrence CK; Adam HJ; Golden A; Berry L; Schweizer F; Zhanel MA; Irfan N; Bay D; Lagacé-Wiens P; Walkty A; Mandell L; Lynch JP; Karlowsky JA
    Drugs; 2021 Feb; 81(2):233-256. PubMed ID: 33247830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-Related Quality of Life as Measured by the 12-Item Short-Form Survey Among Adults With Community-Acquired Bacterial Pneumonia who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials.
    Lodise TP; Colman S; Alexander E; Stein DS; Fitts D; Goldberg L; Schranz J
    Open Forum Infect Dis; 2020 Jun; 7(6):ofaa209. PubMed ID: 32617376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): Data from the Delafloxacin Phase 3 CABP Trial.
    McCurdy S; Nenninger A; Sheets A; Keedy K; Lawrence L; Quintas M; Cammarata S
    Int J Infect Dis; 2020 Aug; 97():374-379. PubMed ID: 32534142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical use of lefamulin: A first-in-class semisynthetic pleuromutilin antibiotic.
    Covvey JR; Guarascio AJ
    J Intern Med; 2022 Jan; 291(1):51-63. PubMed ID: 34425035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lefamulin: Review of a Promising Novel Pleuromutilin Antibiotic.
    Veve MP; Wagner JL
    Pharmacotherapy; 2018 Sep; 38(9):935-946. PubMed ID: 30019769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia.
    Tang HJ; Wang JH; Lai CC
    Medicine (Baltimore); 2020 Jul; 99(29):e21223. PubMed ID: 32702892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group.
    Patel T; Pearl J; Williams J; Haverstock D; Church D
    Respir Med; 2000 Feb; 94(2):97-105. PubMed ID: 10714413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lefamulin: A Novel Semisynthetic Pleuromutilin Antibiotic for Community-acquired Bacterial Pneumonia.
    Watkins RR; File TM
    Clin Infect Dis; 2020 Dec; 71(10):2757-2762. PubMed ID: 32221520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Utility of Lefamulin: If Not Now, When?
    Mercuro NJ; Veve MP
    Curr Infect Dis Rep; 2020; 22(9):25. PubMed ID: 32834786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial.
    McCurdy S; Keedy K; Lawrence L; Nenninger A; Sheets A; Quintas M; Cammarata S
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lefamulin: The First Systemic Pleuromutilin Antibiotic.
    Chahine EB; Sucher AJ
    Ann Pharmacother; 2020 Dec; 54(12):1203-1214. PubMed ID: 32493034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis of atypical pathogens in patients hospitalized with community-acquired respiratory infection.
    Schneeberger PM; Dorigo-Zetsma JW; van der Zee A; van Bon M; van Opstal JL
    Scand J Infect Dis; 2004; 36(4):269-73. PubMed ID: 15198183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia.
    File TM; Rewerska B; Vucinic-Mihailovic V; Gonong JRV; Das AF; Keedy K; Taylor D; Sheets A; Fernandes P; Oldach D; Jamieson BD
    Clin Infect Dis; 2016 Oct; 63(8):1007-1016. PubMed ID: 27448679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.